Collaboration type: One-off campaign
Timeframe: October 2025 – January 2026
Vertical: Biotech / Deep Tech
Startup HQ: Geneva, Switzerland 🇨🇭
Brief
FluoSphera came to us with a genuinely novel story, and a raise of CHF 1.15 million.
Founded in 2021 in Geneva, FluoSphera has developed a multiplexed in vitro platform that allows drug developers to test up to six or seven human tissue models simultaneously in a single well, predicting how compounds behave across organ systems before animal or human trials begin. Over 90% of drug candidates still fail in clinical trials, at an average cost of $2 to $3 billion per new drug developed. FluoSphera’s platform addresses that failure rate with its innovative solution.
The funding round was led by Soulmates Ventures alongside Swiss business angels, with participation from IndieBio New York, a globally recognised deep tech accelerator.
Results
The campaign generated 42 placements across media markets in Europe and beyond, reaching a combined audience of approximately 3 million unique monthly visitors.
Coverage spanned international tech funding press, Swiss and life sciences ecosystem outlets, DACH publications, and Czech business media, with two post-campaign interview placements extending the story’s life well beyond announcement day.
Selected media highlights:
Why It Worked
FluoSphera had a great story that matters. We worked the angles of drug development failure rates, animal testing reduction, human-relevant science. These themes helped FluoSphera resonate far beyond the biotech trade press, and the coverage reflected that.
Having the likes of Soulmates and IndieBio on the cap table added a layer of international credibility that punched above the round size, while Soulmates Ventures’ Czech roots created organic hooks for Central European media that went beyond press release distribution.
Want to see more case studies from Black Unicorn PR? Check these out!
